Matthew B. Klein
CHIEF EXECUTIVE OFFICER at PTC Therapeutics; Director at ClearPoint Neuro. Based in Warren, New Jersey.
- Rank
- 4707th of 14,644
- Companies held
- 2
- Largest holding
- PTCT, 98.5% of total
- Latest SEC filing
- Aug 4, 2026
What the $22.7M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| PTC Therapeutics PTCT Common Stock | Directly | 383,868 | $58.33 | $22.4M | 98.5% | Form 4, Aug 4, 2026 |
| ClearPoint Neuro CLPT Common Stock | Directly | 46,935 | $7.31 | $343K | 1.5% | Form 4, May 21, 2026 |
Share counts are the amounts Matthew B. Klein reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Open-market trades, last 12 months
| Date | Trade | Company | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 4, 2026 | Sold | PTCT | 10,292 | $68.57 | $706K | View |
| May 21, 2026 | Sold | CLPT | 16,000 | $11.59 | $185K | View |
| May 14, 2026 | Sold | PTCT | 7,221 | $73.08 | $528K | View |
| May 14, 2026 | Sold | PTCT | 679 | $73.06 | $50K | View |
| May 14, 2026 | Sold | PTCT | 2,100 | $73.08 | $153K | View |
| May 14, 2026 | Sold | PTCT | 2,572 | $72.46 | $186K | View |
| Apr 21, 2026 | Sold | PTCT | 2,850 | $70.91 | $202K | View |
| Mar 12, 2026 | Sold | PTCT | 2,662 | $64.08 | $171K | View |
| Feb 18, 2026 | Sold | PTCT | 7,371 | $69.36 | $511K | View |
| Jan 8, 2026 | Sold | PTCT | 2,514 | $76.45 | $192K | View |
| Jan 7, 2026 | Sold | PTCT | 3,016 | $77.48 | $234K | View |
| Jan 6, 2026 | Sold | PTCT | 5,149 | $76.95 | $396K | View |
| Dec 30, 2025 | Sold | PTCT | 8,089 | $76.64 | $620K | View |
| Dec 2, 2025 | Sold | PTCT | 3,428 | $79.07 | $271K | View |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 4704 | Ken S. Ansin Director, Independent Bank. Rockland, MA | $22.7M |
| 4705 | Robert H. Herz Director, Morgan Stanley. Ames, IA | $22.7M |
| 4706 | Mark Garrett Director, Snowflake. Menlo Park, CA | $22.7M |
| 4707 | Matthew B. Klein CHIEF EXECUTIVE OFFICER, PTC Therapeutics. Warren, NJ | $22.7M |
| 4708 | Matthew V. Hairford President, Matador Resources. Dallas, TX | $22.7M |
| 4709 | William K. Hood Director, First Guaranty Bancshares. Hammond, LA | $22.7M |
| 4710 | Thomas Nichols Thompson Director, Truist Financial. Charlotte, NC | $22.7M |
Other PTC Therapeutics insiders
All PTCT insiders- Stuart Walter Peltz$15.2MCHIEF EXECUTIVE OFFICER. #6376 overall
- Michael Schmertzler$9.5MDirector. #2219 overall
- Mark Elliott Boulding$6.1MEXEC. VP AND CLO. #12560 overall
- Pierre Gravier$4.9MCHIEF FINANCIAL OFFICER. #14568 overall
- Emily Luisa Hill$2.3MCHIEF FINANCIAL OFFICER. #12562 overall
Questions
How much stock does Matthew B. Klein own?
Matthew B. Klein holds $22,732,196 in listed stock based on SEC filings and current prices, mostly PTC Therapeutics (PTCT). That ranks 4707th on the Stock Rich List.
Is this Matthew B. Klein's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Matthew B. Klein last buy or sell stock?
The most recent open-market trade on file is a sale of 10,292 PTCT shares on Aug 4, 2026 at $68.57.